First Patient Dosed in Artax’s Phase 2a Psoriasis Trial Evaluating AX-158
The first patient has been dosed in the Artax’s Phase 2a trial evaluating the safety and biomarker responses of AX-158 in a first proof of mechanism trial in psoriasis. AX-158 has potential to be the first immunomodulator in the Nck blocker class, the Company states. Safety and efficacy results are expected in second half of 2024. “The new Nck […]